Kenvue Inc

1KVUE

Company Profile

  • Business description

    Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

  • Contact

    1 Kenvue Way
    SummitNJ07901
    USA

    T: +1 908 874-1200

    https://www.kenvue.com

  • Sector

    Consumer Defensive

    Stock type

    Defensive

  • Industry

    Household & Personal Products

    Fiscal Year End

    31 December 2026

    Employees

    22,000

Stocks News & Analysis

stocks

Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?

Amid robust demand for semis, watch for any impact of in-house built chips and whether the supply chain is on track.
stocks

Higher interest rates boost earnings for ASX real estate platform

Interest rates are driving a spike in property listings.
stocks

After earnings, is Palantir a buy, a sell, or fairly valued?

With uncertainty regarding its total addressable market and competitive threats, here’s what we think of Palantir stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,868.304.70-0.05%
CAC 407,979.9276.46-0.95%
DAX 4023,954.93395.35-1.62%
Dow JONES (US)49,760.5656.090.11%
FTSE 10010,265.324.11-0.04%
HKSE26,347.9158.93-0.22%
NASDAQ26,088.20185.92-0.71%
Nikkei 22562,520.11222.46-0.35%
NZX 50 Index13,043.1037.23-0.28%
S&P 5007,400.9611.88-0.16%
S&P/ASX 2008,624.506.50-0.08%
SSE Composite Index4,214.4910.53-0.25%

Market Movers